List of Ozurdex drug patents

Ozurdex is owned by Allergan.

Ozurdex contains Dexamethasone.

Ozurdex has a total of 7 drug patents out of which 6 drug patents have expired.

Expired drug patents of Ozurdex are:

  • US10702539
  • US8506987
  • US8034370
  • US8034366
  • US9192511
  • US10076526

Ozurdex was authorised for market use on 17 June, 2009.

Ozurdex is available in implant;intravitreal dosage forms.

Ozurdex can be used as treatment of macular edema; treatment of uveitis, delivering an ocular implant as described in the dosage and administration section of the approved labeling of ozurdex, treatment of diabetic macular edema; treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo); treatment of non-infectious uveitis affecting the posterior segment of the eye.

The generics of Ozurdex are possible to be released after 01 November, 2023.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10702539 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(21 days ago)

US8506987 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(21 days ago)

US8034370 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(21 days ago)

US8034366 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(21 days ago)

US9192511 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(21 days ago)

US10076526 ALLERGAN Ocular implant made by a double extrusion process
Jan, 2023

(21 days ago)

US6899717 ALLERGAN Methods and apparatus for delivery of ocular implants
Nov, 2023

(8 months from now)

Drugs and Companies using DEXAMETHASONE ingredient

Market Authorisation Date: 17 June, 2009

Treatment: Treatment of diabetic macular edema; Treatment of macular edema following branch retinal vein occlusion (brvo) or central retinal vein occlusion (crvo); Treatment of non-infectious uveitis affecting the posterior segment of the eye; Treatment of macular edema; Treatment of uveitis; Delivering an ocular implant as described in the dosage and administration section of the approved labeling of ozurdex

Dosage: IMPLANT;INTRAVITREAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in